Aurinia Pharmaceuticals, Inc. is a Canadian pharmaceutical company that focuses on developing products for patients with serious medical conditions. They are currently working on LUPKYNIS (voclosporin) for the treatment of lupus nephritis (LN) and other diseases. With an ESG risk rating score of 27.3, Aurinia Pharmaceuticals, Inc. is considered to be of medium risk. The company generates its highest revenue from the United States.